Skip to main content

Advertisement

SpringerLink
Log in

Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA

  • Female Urology (K Kobashi, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) with or without a neurogenic etiology that is refractory to conventional first-, second-, and third-line therapies is a challenging condition that typically leaves the physician and the patient with few options. Historically, treatment for patients who did not respond to any of the few pharmacologic choices focused on more invasive surgical options—specifically, augmentation cystoplasty (AC). In 2011 and 2013, the Food and Drug Administration (FDA) approved intradetrusor injection of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO), respectively. Since then, a dramatic decline in the use of AC has called into question its utility in the treatment algorithm of this difficult patient population. The purpose of this paper is to review the current body of literature in order to outline the circumstances in which AC is still a relevant therapeutic option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wein AJ. Re: an International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. J Urol. 2011;185(5):1812.

    Article  PubMed  Google Scholar 

  2. Gormley EA et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6):2455–63.

    Article  PubMed  Google Scholar 

  3. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109(9):1280–93.

    Article  PubMed  Google Scholar 

  4. Zajaczkowski T. Johann Anton von Mikulicz-Radecki (1850–1905)—a pioneer of gastroscopy and modern surgery: his credit to urology. World J Urol. 2008;26(1):75–86.

    Article  PubMed  Google Scholar 

  5. Couvelaire R. La petite vessie des tuberculeux genito-urinaires: essai de classifi cation, places et variantes des cysto-intestinoplasties. J Urol (Paris) 1950; 56: 381–434 Leong CH. Use of the stomach for bladder replacement and urinary diversion. Ann R Coll Surg Engl 1978; 60: 283–9

  6. Bramble FJ. The treatment of adult enuresis and urge incontinence by enterocystoplasty. Br J Urol. 1982;54(6):693–6.

    Article  CAS  PubMed  Google Scholar 

  7. Adams MC, Mitchell ME, Rink RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol. 1988;140.5(Pt 2):1152–6.

    Google Scholar 

  8. Reyblat P, Ginsberg DA. Augmentation cystoplasty: what are the indications? Curr Urol Rep. 2008;9(6):452–8.

    Article  PubMed  Google Scholar 

  9. Khastgir J et al. Surgical and patient reported outcomes of ‘clam’augmentation ileocystoplasty in spinal cord injured patients. Eur Urol. 2003;43(3):263–9.

    Article  CAS  PubMed  Google Scholar 

  10. Zachoval R et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int. 2003;70(1):21–6.

    Article  PubMed  Google Scholar 

  11. Bhatnagar V et al. Augmentation colocystoplasty in bladder exstrophy. Pediatr Surg Int. 2002;18(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  12. Surer I et al. Continent urinary diversion and the exstrophy-epispadias complex. J Urol. 2003;169(3):1102–5.

    Article  PubMed  Google Scholar 

  13. Youssif M et al. Augmentation ureterocystoplasty in boys with valve bladder syndrome. J Pediatr Urol. 2007;3(6):433–7.

    Article  PubMed  Google Scholar 

  14. Krieger JN, Stubenbord WT, Vaughan Jr ED. Transplantation in children with end stage renal disease of urologic origin. J Urol. 1980;124(4):508–12.

    CAS  PubMed  Google Scholar 

  15. Thomalla JV et al. Renal transplantation into the reconstructed bladder. J Urol. 1989;141(2):265–8.

    CAS  PubMed  Google Scholar 

  16. Basiri A, Hosseini Moghaddam SMM, Khoddam R. Augmentation cystoplasty before and after renal transplantation: long-term results. Transplant Proc. 2002;34(6). Elsevier.

  17. Nahas WC et al. Augmentation cystoplasty in renal transplantation: a good and safe option—experience with 25 cases. Urology. 2002;60(5):770–4.

    Article  PubMed  Google Scholar 

  18. Capizzi A et al. Kidney transplantation in children with reconstructed bladder. Transplantation. 2004;77(7):1113–6.

    Article  CAS  PubMed  Google Scholar 

  19. Pereira PL et al. Does bladder augmentation negatively affect renal transplant outcome in posterior urethral valve patients? J Pediatr Urol. 2014;10(5):892–7.

    Article  Google Scholar 

  20. Fantl JA et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.

    Article  CAS  PubMed  Google Scholar 

  21. Goode PS et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50(5):808–16.

    Article  PubMed  Google Scholar 

  22. Kaya S, Akbayrak T, Beksaç S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25(4):327–38.

    Article  PubMed  Google Scholar 

  23. Arruda RM et al. Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. Int Urogynecol J. 2008;19(8):1055–61.

    Article  Google Scholar 

  24. Colombo M et al. Oxybutynin and bladder training in the management of female urinary urge incontinence: a randomized study. Int Urogynecol J. 1995;6(2):63–7.

    Article  Google Scholar 

  25. Burgio KL et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.

    Article  CAS  PubMed  Google Scholar 

  26. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study.

  27. Abrams P et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81(6):801–10.

    Article  CAS  PubMed  Google Scholar 

  28. Siegel S et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6‐months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.

    Article  PubMed  Google Scholar 

  29. Nitti V, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2012;189:2186–93.

    Article  PubMed  Google Scholar 

  30. Osborn D, Dmochowski R, Reynolds WS, et al. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dmochowski R, Chapple C, Nitti V, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–22.

    Article  CAS  PubMed  Google Scholar 

  32. Schulte-Baukloh H et al. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology. 2002;59(3):325–7.

    Article  CAS  PubMed  Google Scholar 

  33. Brubaker L et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Flynn MK et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sahai A et al. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.

    Article  CAS  PubMed  Google Scholar 

  36. Duthie, James B., et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Library (2007)

  37. Apostolidis A et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–20.

    Article  CAS  PubMed  Google Scholar 

  38. Schurch B et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.

    Article  CAS  PubMed  Google Scholar 

  39. Mohee A et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–13.

    Article  CAS  PubMed  Google Scholar 

  40. Sager C et al. Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type A. ISRN Urol. 2012;2012:763159.

    PubMed  PubMed Central  Google Scholar 

  41. Riccabona M et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 2004;171(2):845–8.

    Article  CAS  PubMed  Google Scholar 

  42. Department of Health, UK. Hospital episode statistics. Department of Health, UK. http://www.hesonline.nhs.uk.

  43. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88(6):511–25.

    Article  CAS  PubMed  Google Scholar 

  44. El-Azab AS, Moeen AM. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty. Arab J Urol. 2013;11(4):344–9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Smith RB, van Cangh P, Skinner DG, Kauffman JJ, Goodwin WE. Augmentation enterocystoplasty: a critical review. J Urol. 1977;1(1):35–9.

    Google Scholar 

  46. Elzawahri A, Bissada NK, Herchorn S, Aboul-Enein H, Ghoneim M, Bissada MA. Urinary conduit formation using a retubularized bowel from continent urinary diversion or intestinal augmentations: does it have a role in patients with interstitial cystitis? J Urol. 2004;171:1559–62.

    Article  PubMed  Google Scholar 

  47. Reyblat P, Ginsberg DA. Evaluation and management of failed bladder augment. Curr Bladder Dysfunction Rep. 2012;7(4):302–8.

    Article  Google Scholar 

  48. Apostolidis A et al. Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty. Nat Clin Pract Urol. 2007;4(5):280–4.

    Article  CAS  PubMed  Google Scholar 

  49. Rasmussen NT, Guralnick ML, O’Connor RC. Successful use of sacral neuromodulation after failed bladder augmentation. Can Urol Assoc J. 2009;3(5):E49.

    PubMed  PubMed Central  Google Scholar 

  50. Vajda P et al. A therapeutic method for failed bladder augmentation in children: re-augmentation. BJU Int. 2006;97(4):816–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Stony Brook University Hospital, HSC Level 9 Rm 040, Stony Brook, NY, 11794, USA

    Evan Shreck

  2. Department of Urology, Virginia Mason, Buck Level 7, Seattle, WA, 98101, USA

    Kevin Gioia & Alvaro Lucioni

Authors
  1. Evan Shreck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Gioia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alvaro Lucioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro Lucioni.

Ethics declarations

Conflict of Interest

Evan Shreck and Kevin Gioia each declare no potential conflicts of interest.

Alvaro Lucioni reports personal fees from AMS/Boston Scientific.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Female Urology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shreck, E., Gioia, K. & Lucioni, A. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA. Curr Urol Rep 17, 27 (2016). https://doi.org/10.1007/s11934-016-0585-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-016-0585-3

Keywords

Search

Navigation